BR-101801 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to GlobalData, Phase I drugs for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BR-101801 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-101801 overview
BR-101801 is under development for the treatment of relapsed/refractory B-cell lymphomas including mantle cell lymphoma, marginal zone lymphoma, Waldensian's macroglobulinemia, chronic lymphocytic leukemia, peripheral T-cell lymphomas, follicular lymphoma and angioimmunoblastic T-cell lymphoma (AITL). It acts by targeting DNA activated protein kinase (DNA-PK), phosphatidylinositol 3 kinase delta (PI3Kdelta) and (PI3KGamma). It is administered through oral route. It was under development for the treatment of diffuse large B-cell lymphoma,.
Boryung Pharmaceutical overview
Boryung Pharmaceutical (Boryung)is a pharmaceutical company. It manufactures and distributes pharmaceutical products including cardiovascular, anticancer and gastrointestinal drugs. The company offers products such as kanarb, gelfos, maxpim injection, mayact tablet, among others. The company’s product portfolio focusses on the chronical diseases including hypertension, dyslipidemia, diabetes, CNS disorders, and cancers. It also offers products including Dukarb Plus, Zepzelca, Finjuve Spray, among others. The company also provides marketed API along with anti-cancer injection facilities. Boryung is headquartered in Seoul, South Korea.
For a complete picture of BR-101801’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
